Zachary Owen

Mr. Zachary Owen

Biomedical Engineering, University of Glasgow, Glasgow, Glasgow City, UK
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2016 in Chemical Communications
Verified
Journal Article
Open access
PDF file
ICIgnacio Colomer
Ignacio Colomer
CEChristopher J. Empson
Christopher J. Empson
PCPhilip Craven
Philip Craven
Zachary OwenZachary Owen
Zachary Owen
RDRichard G. Doveston
Richard G. Doveston
ANAdam Nelson
Adam Nelson
LLAMA was used to assess the lead-likeness of scaffolds prepared via complementary cyclisations of hex-2-ene-1,6-diamine derivatives.

1 April 2020 in SLAS Technology
Verified
Journal Article
Open access
PDF file
DJDimitris Josephides
Dimitris Josephides
SDSerena Davoli
Serena Davoli
WWWilliam Whitley
William Whitley
RRRaphael Ruis
Raphael Ruis
RSRobert Salter
Robert Salter
DHDavid Holmes
David Holmes
The primary goal of bioprocess cell line development is to obtain high product yields from robustly growing and well-defined clonal cell lines in timelines measured in weeks rather than months. Likewise, high-throughput screening of B cells and hybridomas is required for most cell line engineering workflows. A substantial bottleneck in these processes is detecting and isolating rare clonal cells with the required characteristics. Traditionally, this was achieved by the resource-intensive method of limiting dilution cloning, and more recently aided by semiautomated technologies such as cell sorting (e.g., fluorescence-activated cell sorting) and colony picking. In this paper we report on our novel Cyto-Mine Single Cell Analysis and Monoclonality Assurance System, which overcomes the limitations of current technologies by screening hundreds of thousands of individual cells for secreted target proteins, and then isolating and dispensing the highest producers into microtiter plate wells (MTP). The Cyto-Mine system performs this workflow using a fully integrated, microfluidic Cyto-Cartridge. Critically, all reagents and Cyto-Cartridges used are animal component-free (ACF) and sterile, thus allowing fast, robust, and safe isolation of desired cells.

11 November 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
AMAntonia Molloy
Antonia Molloy
JHJames Harrison
James Harrison
JMJohn S McGrath
John S McGrath
Zachary OwenZachary Owen
Zachary Owen
CSClive Smith
Clive Smith
Jonathan A.G. CoxJonathan A.G. Cox
Jonathan A.G. Cox
Tuberculosis (TB) remains a global healthcare crisis, with an estimated 5.8 million new cases and 1.5 million deaths in 2020. TB is caused by infection with the major human pathogen Mycobacterium tuberculosis, which is difficult to rapidly diagnose and treat. There is an urgent need for new methods of diagnosis, sufficient in vitro models that capably mimic all physiological conditions of the infection, and high-throughput drug screening platforms. Microfluidic-based techniques provide single-cell analysis which reduces experimental time and the cost of reagents, and have been extremely useful for gaining insight into monitoring microorganisms. This review outlines the field of microfluidics and discusses the use of this novel technique so far in M. tuberculosis diagnostics, research methods, and drug discovery platforms. The practices of microfluidics have promising future applications for diagnosing and treating TB.

29 September 2021 in Preprints.org
Verified
Preprint
Open access
AMAntonia Molloy
Antonia Molloy
JHJames Harrison
James Harrison
JMJohn McGrath
John McGrath
Zachary OwenZachary Owen
Zachary Owen
CSClive Smith
Clive Smith
Jonathan A.G. CoxJonathan A.G. Cox
Jonathan A.G. Cox
Tuberculosis (TB) remains a global healthcare crisis with an estimated 10 million new cases and 1.4 million deaths per year TB is caused by infection with the major human pathogen Mycobacte-rium tuberculosis, which is difficult to rapidly diagnose and treat. There is an urgent need for new methods of diagnosis, sufficient in vitro models which capably mimic all physiological condi-tions of the infection, and high-throughput drug screening platforms. Microfluidic-based tech-niques provide single-cell analysis which reduces experimental time, the cost of reagents, and have been extremely useful for gaining insight into monitoring microorganisms. This review out-lines the field of microfluidics and discusses the use of this novel technique so far in M. tuberculo-sis diagnostics, research methods, and drug discovery platforms. The practices of microfluidics have promising future applications for diagnosing and treating TB.